thiorphan has been researched along with Colorectal Neoplasms in 4 studies
Thiorphan: A potent inhibitor of membrane metalloendopeptidase (ENKEPHALINASE). Thiorphan potentiates morphine-induced ANALGESIA and attenuates naloxone-precipitated withdrawal symptoms.
Colorectal Neoplasms: Tumors or cancer of the COLON or the RECTUM or both. Risk factors for colorectal cancer include chronic ULCERATIVE COLITIS; FAMILIAL POLYPOSIS COLI; exposure to ASBESTOS; and irradiation of the CERVIX UTERI.
| Excerpt | Relevance | Reference |
|---|---|---|
| " The first cohort of 14 consecutive patients explored for the mechanism of diarrhea received acetorphan (a new enkephalinase inhibitor) 100 mg three times daily; the second 14-patient cohort received, in addition to acetorphan, loperamide 4 mg three times daily." | 9.08 | Pathophysiology and therapy of irinotecan-induced delayed-onset diarrhea in patients with advanced colorectal cancer: a prospective assessment. ( Bastian, G; Bonnay, M; Cote, C; Cvitkovic, E; Hagipantelli, R; Herait, P; Mahjoubi, M; Mignard, D; Misset, JL; Saliba, F; Vassal, G, 1998) |
| " The first cohort of 14 consecutive patients explored for the mechanism of diarrhea received acetorphan (a new enkephalinase inhibitor) 100 mg three times daily; the second 14-patient cohort received, in addition to acetorphan, loperamide 4 mg three times daily." | 5.08 | Pathophysiology and therapy of irinotecan-induced delayed-onset diarrhea in patients with advanced colorectal cancer: a prospective assessment. ( Bastian, G; Bonnay, M; Cote, C; Cvitkovic, E; Hagipantelli, R; Herait, P; Mahjoubi, M; Mignard, D; Misset, JL; Saliba, F; Vassal, G, 1998) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (50.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 1 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Mizerska-Kowalska, M | 1 |
| Kreczko-Kurzawa, J | 1 |
| Zdzisińska, B | 1 |
| Czerwonka, A | 1 |
| Sławińska-Brych, A | 1 |
| Maćkiewicz, Z | 1 |
| Nidzworski, D | 1 |
| Kandefer-Szerszeń, M | 1 |
| Dorval, ED | 1 |
| Regimbeau, C | 1 |
| Gamelin, E | 1 |
| Picon, L | 1 |
| Bérard, H | 1 |
| Saliba, F | 1 |
| Hagipantelli, R | 1 |
| Misset, JL | 1 |
| Bastian, G | 1 |
| Vassal, G | 1 |
| Bonnay, M | 1 |
| Herait, P | 2 |
| Cote, C | 1 |
| Mahjoubi, M | 1 |
| Mignard, D | 2 |
| Cvitkovic, E | 1 |
| Freyer, G | 1 |
| Rougier, P | 1 |
| Bugat, R | 1 |
| Droz, JP | 1 |
| Marty, M | 1 |
| Bleiberg, H | 1 |
| Awad, L | 1 |
| Culine, S | 1 |
| Trillet-Lenoir, V | 1 |
3 trials available for thiorphan and Colorectal Neoplasms
| Article | Year |
|---|---|
[Treatment of acute chemically induced diarrhea by inhibition of enkephalinase. Results of a pilot study].
Topics: Acute Disease; Adenocarcinoma; Adult; Aged; Colorectal Neoplasms; Combined Modality Therapy; Diarrhe | 1995 |
Pathophysiology and therapy of irinotecan-induced delayed-onset diarrhea in patients with advanced colorectal cancer: a prospective assessment.
Topics: Adult; Aged; Antidiarrheals; Antineoplastic Agents, Phytogenic; Camptothecin; Colorectal Neoplasms; | 1998 |
Prognostic factors for tumour response, progression-free survival and toxicity in metastatic colorectal cancer patients given irinotecan (CPT-11) as second-line chemotherapy after 5FU failure. CPT-11 F205, F220, F221 and V222 study groups.
Topics: Adult; Aged; Antidiarrheals; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Cam | 2000 |
1 other study available for thiorphan and Colorectal Neoplasms
| Article | Year |
|---|---|
Neutral endopeptidase (NEP) inhibitors - thiorphan, sialorphin, and its derivatives exert anti-proliferative activity towards colorectal cancer cells in vitro.
Topics: Adaptor Proteins, Signal Transducing; Apoptosis; Cell Cycle Proteins; Cell Line, Tumor; Cell Prolife | 2019 |